U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07307638) titled 'Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants' on Dec. 15.
Brief Summary: ZT006 is an oral, long-acting glucagon-like peptide-1. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT006 in healthy, overweight and obese participants. The study comprises three parts, i.e. single dose-escalation, multiple dose-escalation, food effect on the pharmacokinetics of ZT006.
In the single dose-escalation study, participants will receive a single dose (ZT006 dose level 1 - 5 or corresponding placebo) of ZT006 under fasted condition....